IRF5 and systemic lupus erythematosus: Thus, there was a critical threshold level of IRF5 expression in B cells that was necessary to induce disease, and this suggests that future therapeutic approaches targeting IRF5 in SLE will need to effectively reduce IRF5 expression or activity in B cells.